E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Lonial, Sagar; Jacobus, Susanna J.; Weiss, Matthias; Kumar, Shaji; Orlowski, Robert Z.; Kaufman, Jonathan L.; Yacoub, Abdulraheem; Buadi, Francis; O'Brien, Timothy E.; Matous, Jeffrey; Anderson, Daniel M.; Emmons, Robert; Dhodapkar, Madhav V.; Wagner, Lynne I.; Rajkumar, S. Vincent

doi:10.1200/jco.2019.37.15_suppl.8001

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

8001 Background: Smoldering multiple myeloma (SMM) is a precursor to myeloma, wherein current standard of care is observation (obs). Data from a randomized Spanish trial (Mateos et al, NEJM 2015) suggest that lenalidomide(len)/dexamethasone improves time to developing myeloma (TTP) and overall su…